Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Lexicon Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Lexicon Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01677910
First received: August 30, 2012
Last updated: November 6, 2014
Last verified: November 2014

August 30, 2012
November 6, 2014
October 2012
March 2016   (final data collection date for primary outcome measure)
  • Change from baseline in number of daily bowel movements [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Incidence of treatment-emergent adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Change from baseline in number of daily bowel movements [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01677910 on ClinicalTrials.gov Archive Site
  • Change from baseline in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in the number of cutaneous flushing episodes [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in abdominal pain [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in stool consistency [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in the number of cutaneous flushing episodes [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in abdominal pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change in the frequency of rescue short-acting somatostatin analog [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Incidence of treatment-emergent adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy

The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Carcinoid Syndrome
  • Drug: Telotristat etiprate tablets (250 mg)
    Other Name: LX1606
  • Drug: Placebo tablets
    One placebo tablet administered three times daily
  • Experimental: 250 mg telotristat etiprate
    One telotristat etiprate (250 mg) tablet administered three times daily
    Intervention: Drug: Telotristat etiprate tablets (250 mg)
  • Experimental: 500 mg telotristat etiprate
    Two telotristat etiprate (250 mg) tablets administered three times daily
    Intervention: Drug: Telotristat etiprate tablets (250 mg)
  • Placebo Comparator: Placebo
    Placebo administered three times daily
    Intervention: Drug: Placebo tablets
  • Experimental: 500 mg telotristat etiprate open label extension
    Two 250 mg telotristat etiprate tablets three times daily in a 36-week open-label Extension period
    Intervention: Drug: Telotristat etiprate tablets (250 mg)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
105
Not Provided
March 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor
  • Documented history of carcinoid syndrome and currently experiencing ≥4 bowel movements per day during the Run-in period
  • Currently receiving stable-dose somatostatin analog (SSA) therapy
  • Minimum dose of LAR or depot SSA therapy

    • Octreotide LAR at 30 mg every 4 weeks
    • Lanreotide Depot at 120 mg every 4 weeks
    • Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose
  • Ability and willingness to provide written informed consent

Exclusion Criteria:

  • Presence of diarrhea attributed to any condition(s) other than carcinoid syndrome
  • Karnofsky Performance status ≤60%
  • Treatment with any tumor directed therapy, including interferon, chemotherapy, mTOR inhibitors ≤4 weeks prior to Screening, or hepatic embolization, radiotherapy, radiolabelled SSA, and/or tumor debulking ≤12 weeks prior to Screening
  • History of short bowel syndrome (SBS)
  • Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study, or QTcF >450 ms
  • Previous exposure to telotristat etiprate
Both
18 Years and older
No
Contact: Shanna Jackson, Project manager 281-863-3000 clinicalinfo@lexpharma.com
United States,   Australia,   Belgium,   Canada,   France,   Germany,   Italy,   Netherlands,   Spain,   Sweden,   United Kingdom
 
NCT01677910
LX1606.1-301-CS, LX1606.301
Yes
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Not Provided
Study Director: Pablo Lapuerta, MD Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP